|
1
|
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
|
Hepatology
|
2014
|
3.31
|
|
2
|
Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology.
|
Hepatology
|
2010
|
2.38
|
|
3
|
Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.
|
J Hepatol
|
2009
|
2.21
|
|
4
|
Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
|
J Gastroenterol Hepatol
|
2009
|
2.16
|
|
5
|
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
|
Hepatology
|
2006
|
1.93
|
|
6
|
Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study.
|
J Med Virol
|
2013
|
1.86
|
|
7
|
Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.78
|
|
8
|
Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area.
|
Liver Int
|
2011
|
1.77
|
|
9
|
Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center.
|
J Hepatol
|
2007
|
1.72
|
|
10
|
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
|
Hepatology
|
2009
|
1.66
|
|
11
|
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
|
Cancer Chemother Pharmacol
|
2011
|
1.61
|
|
12
|
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells.
|
J Hepatol
|
2008
|
1.56
|
|
13
|
Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
|
Radiology
|
2011
|
1.36
|
|
14
|
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
|
Radiology
|
2013
|
1.24
|
|
15
|
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
|
J Gastroenterol Hepatol
|
2011
|
1.23
|
|
16
|
Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma.
|
PLoS One
|
2013
|
1.22
|
|
17
|
Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors.
|
J Gastroenterol
|
2007
|
1.17
|
|
18
|
Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
|
J Gastroenterol Hepatol
|
2011
|
1.12
|
|
19
|
Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea.
|
J Gastroenterol Hepatol
|
2003
|
1.12
|
|
20
|
Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma.
|
Cancer
|
2002
|
1.09
|
|
21
|
(4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
|
J Nucl Med
|
2012
|
1.07
|
|
22
|
Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
|
Ann Surg Oncol
|
2009
|
1.05
|
|
23
|
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
|
Jpn J Clin Oncol
|
2010
|
1.05
|
|
24
|
Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.
|
Liver Int
|
2013
|
1.04
|
|
25
|
Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
|
J Hepatol
|
2010
|
1.04
|
|
26
|
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.
|
J Hepatol
|
2003
|
1.03
|
|
27
|
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
|
Cancer
|
2012
|
1.02
|
|
28
|
Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma.
|
Ann Surg
|
2015
|
1.01
|
|
29
|
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).
|
Liver Int
|
2013
|
1.00
|
|
30
|
Emergency adult-to-adult living-donor liver transplantation for acute liver failure in a hepatitis B virus endemic area.
|
Hepatology
|
2010
|
0.99
|
|
31
|
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
|
Mol Cancer Res
|
2010
|
0.98
|
|
32
|
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.
|
Antimicrob Agents Chemother
|
2012
|
0.97
|
|
33
|
Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis.
|
Ann Surg Oncol
|
2012
|
0.96
|
|
34
|
Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
|
Oncology
|
2012
|
0.96
|
|
35
|
Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
|
Antivir Ther
|
2012
|
0.95
|
|
36
|
Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis.
|
J Gastroenterol Hepatol
|
2014
|
0.94
|
|
37
|
Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.
|
J Clin Gastroenterol
|
2002
|
0.93
|
|
38
|
EUS-guided drainage of hepatic abscesses not accessible to percutaneous drainage (with videos).
|
Gastrointest Endosc
|
2010
|
0.93
|
|
39
|
Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma.
|
Oncology
|
2012
|
0.92
|
|
40
|
Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors.
|
J Gastroenterol Hepatol
|
2012
|
0.92
|
|
41
|
Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.
|
Ann Surg Oncol
|
2009
|
0.91
|
|
42
|
Role of additional angiography and chemoembolization in patients with hepatocellular carcinoma who achieved complete necrosis following transarterial chemoembolization.
|
J Gastroenterol Hepatol
|
2004
|
0.91
|
|
43
|
Behavioral and healthcare-associated risk factors for chronic hepatitis C virus infection in Korea.
|
J Korean Med Sci
|
2012
|
0.90
|
|
44
|
Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization.
|
Ann Surg Oncol
|
2007
|
0.90
|
|
45
|
Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy.
|
Hepatology
|
2014
|
0.89
|
|
46
|
Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis.
|
J Gastroenterol Hepatol
|
2011
|
0.89
|
|
47
|
Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine.
|
J Gastroenterol Hepatol
|
2002
|
0.88
|
|
48
|
Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma.
|
Eur J Gastroenterol Hepatol
|
2004
|
0.88
|
|
49
|
Hepatic myelopathy as a presenting neurological complication in patients with cirrhosis and spontaneous splenorenal shunt.
|
Korean J Hepatol
|
2008
|
0.88
|
|
50
|
Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center.
|
Korean J Hepatol
|
2011
|
0.87
|
|
51
|
Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma.
|
Ann Surg
|
2013
|
0.87
|
|
52
|
Acute hepatitis C in Korea: different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion.
|
J Med Virol
|
2011
|
0.87
|
|
53
|
[Clinical and microbiological characteristics of spontaneous bacterial peritonitis (SBP) in a recent five year period].
|
Taehan Kan Hakhoe Chi
|
2002
|
0.86
|
|
54
|
Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling.
|
PLoS One
|
2012
|
0.86
|
|
55
|
Switch of cadherin expression from E- to N-type during the activation of rat hepatic stellate cells.
|
Histochem Cell Biol
|
2006
|
0.86
|
|
56
|
[Usefulness of reagent strips for the diagnosis of spontaneous bacterial peritonitis].
|
Korean J Hepatol
|
2005
|
0.86
|
|
57
|
Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma.
|
J Hepatol
|
2011
|
0.86
|
|
58
|
Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns.
|
Hepatol Res
|
2013
|
0.85
|
|
59
|
Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
|
J Vasc Interv Radiol
|
2013
|
0.85
|
|
60
|
Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment.
|
Liver Int
|
2014
|
0.85
|
|
61
|
High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.
|
Clin Mol Hepatol
|
2013
|
0.85
|
|
62
|
Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on.
|
Liver Transpl
|
2011
|
0.85
|
|
63
|
Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea?
|
J Clin Gastroenterol
|
2004
|
0.84
|
|
64
|
Predicting survival after living and deceased donor liver transplantation in adult patients with acute liver failure.
|
J Gastroenterol
|
2012
|
0.84
|
|
65
|
rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.
|
J Gastroenterol Hepatol
|
2012
|
0.84
|
|
66
|
Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
|
Antimicrob Agents Chemother
|
2009
|
0.83
|
|
67
|
Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
|
J Gastroenterol Hepatol
|
2005
|
0.83
|
|
68
|
Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study.
|
Am J Clin Oncol
|
2015
|
0.83
|
|
69
|
Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.
|
Liver Transpl
|
2013
|
0.82
|
|
70
|
RPS3a over-expressed in HBV-associated hepatocellular carcinoma enhances the HBx-induced NF-κB signaling via its novel chaperoning function.
|
PLoS One
|
2011
|
0.82
|
|
71
|
Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization.
|
Dig Dis Sci
|
2013
|
0.82
|
|
72
|
Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy.
|
J Gastroenterol Hepatol
|
2004
|
0.81
|
|
73
|
Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots.
|
Am J Gastroenterol
|
2002
|
0.81
|
|
74
|
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
|
Medicine (Baltimore)
|
2016
|
0.81
|
|
75
|
Clinical implications of arrest-defective protein 1 expression in hepatocellular carcinoma: a novel predictor of microvascular invasion.
|
Dig Dis
|
2012
|
0.81
|
|
76
|
Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule.
|
J Hepatol
|
2007
|
0.80
|
|
77
|
[Clinical features of fulminant hepatic failure in a tertiary hospital with a liver transplant center in Korea].
|
Korean J Hepatol
|
2006
|
0.80
|
|
78
|
Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma.
|
J Gastroenterol Hepatol
|
2013
|
0.80
|
|
79
|
Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report.
|
Korean J Hepatol
|
2012
|
0.79
|
|
80
|
Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6.
|
Clin Mol Hepatol
|
2013
|
0.79
|
|
81
|
Effect of response to interferon-α therapy on the occurrence of hepatocellular carcinoma in patients with chronic hepatitis B.
|
Dig Dis
|
2012
|
0.78
|
|
82
|
Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
|
Korean J Hepatol
|
2009
|
0.78
|
|
83
|
Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy.
|
Liver Int
|
2009
|
0.78
|
|
84
|
Cholestyramine resin for erythropoietic protoporphyria with severe hepatic disease: a case report.
|
Korean J Hepatol
|
2010
|
0.78
|
|
85
|
Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation.
|
Liver Transpl
|
2014
|
0.77
|
|
86
|
High HBV-DNA titer in surrounding liver rather than in hepatocellular carcinoma tissue predisposes to recurrence after curative surgical resection.
|
J Clin Gastroenterol
|
2012
|
0.77
|
|
87
|
Lack of association between hepatitis B virus pre-S mutations and recurrence after surgical resection in hepatocellular carcinoma.
|
J Med Virol
|
2013
|
0.77
|
|
88
|
[Therapeutic efficacy of transjugular intrahepatic portosystemic shunt on bleeding gastric varices].
|
Taehan Kan Hakhoe Chi
|
2002
|
0.77
|
|
89
|
Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients.
|
Virol J
|
2012
|
0.77
|
|
90
|
[Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
|
Taehan Kan Hakhoe Chi
|
2002
|
0.77
|
|
91
|
Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation.
|
J Gastrointest Surg
|
2011
|
0.76
|
|
92
|
Liver function tests as indicators of metabolic syndrome.
|
Korean J Hepatol
|
2011
|
0.76
|
|
93
|
Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.
|
J Gastroenterol Hepatol
|
2007
|
0.76
|
|
94
|
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
|
Antimicrob Agents Chemother
|
2013
|
0.76
|
|
95
|
Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma.
|
J Magn Reson Imaging
|
2014
|
0.76
|
|
96
|
Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.
|
Eur J Gastroenterol Hepatol
|
2003
|
0.75
|
|
97
|
Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma.
|
J Hepatol
|
2012
|
0.75
|
|
98
|
Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B.
|
Gut Liver
|
2007
|
0.75
|
|
99
|
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
|
J Korean Med Sci
|
2011
|
0.75
|
|
100
|
Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
|
Antivir Ther
|
2013
|
0.75
|
|
101
|
Osler-Weber-Rendu disease presenting with hepatocellular carcinoma: radiologic and genetic findings.
|
Korean J Hepatol
|
2011
|
0.75
|
|
102
|
Noninvasive diagnostic criteria for hepatocellular carcinoma.
|
Clin Mol Hepatol
|
2012
|
0.75
|
|
103
|
Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C.
|
Korean J Intern Med
|
2009
|
0.75
|
|
104
|
Role of Computed Tomography Volumetry in Estimating Liver Weights in Surgical Patients with Hepatic Steatosis.
|
Exp Clin Transplant
|
2017
|
0.75
|
|
105
|
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
|
Am J Clin Oncol
|
2017
|
0.75
|
|
106
|
[Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].
|
Korean J Hepatol
|
2010
|
0.75
|
|
107
|
Clinical usefulness of endoscopic palliation in patients with biliary obstruction caused by hepatocellular carcinoma.
|
Digestion
|
2013
|
0.75
|
|
108
|
[The effects of tamoxifen on human hepatocellular carcinoma cell proliferation and transforming growth factor-beta1 expression].
|
Taehan Kan Hakhoe Chi
|
2003
|
0.75
|
|
109
|
[Validation of international autoimmune hepatitis group scoring system for diagnosis of type 1 autoimmune hepatitis in Korea].
|
Taehan Kan Hakhoe Chi
|
2002
|
0.75
|
|
110
|
Antifibrogenic effects of tamoxifen in a rat model of periportal hepatic fibrosis.
|
Liver Int
|
2008
|
0.75
|
|
111
|
Prognostic value of hepatocyte nuclear factors 4α and 1α identified by tissue microarray in resectable hepatocellular carcinoma.
|
J Gastroenterol Hepatol
|
2014
|
0.75
|